Infantile Acne: Persistent Neonatal-Onset Acne Indicating Androgen Excess

Clinical Overview

Infantile acne refers to acne persisting beyond 3-4 months of age or acne with onset after 3-4 months in infants younger than 1-2 years. Unlike neonatal acne (which results from transplacental maternal androgens and is self-limited), infantile acne indicates abnormally elevated androgen production from the infant's own adrenal glands or other endocrine pathology. The condition requires systematic investigation for underlying hormonal abnormalities including congenital adrenal hyperplasia (CAH), adrenal tumors, and other androgen-producing conditions. Early recognition and endocrinologic evaluation prevent progression to severe acne and identify systemic endocrine pathology requiring treatment.

Epidemiology

Infantile acne is rare, affecting 1-2% of infants (compared to 20-40% with neonatal acne). Peak presentation is 3-12 months of age, though can occur through 3-4 years (true infantile acne persists longer than neonatal acne). Slight male predominance (1.3:1). Most common associated endocrine diagnosis is congenital adrenal hyperplasia (CAH), particularly 21-hydroxylase deficiency, found in 10-15% of infantile acne cases. Other causes: adrenal tumors (5% of cases), apparent mineralocorticoid excess (AME), and idiopathic androgen excess (20-30% of cases with no identified cause but elevated androgens). Severity of infantile acne varies from mild papulopustular lesions to extensive nodular acne resembling adolescent severe acne.

Pathophysiology

Infantile acne results from elevated androgen levels from infant's own endocrine system rather than maternal hormone transfer. Pathophysiology parallels adolescent acne but occurs pathologically early. Elevated androgens (testosterone, androstenedione, DHEA-S) stimulate sebaceous gland hyperplasia and sebum production. Adrenal sources of androgens: (1) 21-hydroxylase deficiency (most common CAH form, 90-95% of CAH) blocks cortisol synthesis, shunting steroid precursors to androgen pathway, creating 17-hydroxyprogesterone accumulation; (2) 11β-hydroxylase deficiency (5-10% of CAH) similarly causes androgen excess; (3) 3β-HSD deficiency (rare, <1% of CAH) causes DHEA-S elevation. Adrenal tumors (benign adenomas, rarely malignant) produce autonomous androgen secretion. Follicular hyperkeratinization and C. acnes proliferation proceed similarly to adolescent acne. Severity correlates with androgen excess magnitude.

Clinical Presentation

Infantile acne presents as persistent or worsening papulopustular eruptions beyond 3-4 months of age or initial onset after 3-4 months. Distribution typically includes face, chest, and back (sebaceous gland-rich areas). Lesions are predominantly inflammatory papules and pustules, occasionally with nodules if severe. Unlike neonatal acne (predominantly comedonal), infantile acne shows significant inflammatory component. Severity ranges from scattered papules to extensive nodular acne resembling adolescent severe acne. Associated findings: accelerated linear growth (excessive androgen stimulates growth hormone axis), premature pubic or axillary hair development (terminal hair growth from androgens), and clitoromegaly in females (from in utero androgen exposure in CAH). Virilization (male-pattern hair growth, voice deepening) in females suggests significant androgen excess (often from adrenal tumor or severe CAH).

Diagnosis

Clinical diagnosis requires: (1) confirmation of acne persistence beyond 3-4 months (distinguishing from self-limited neonatal acne); (2) assessment for signs of androgen excess (accelerated growth, premature terminal hair development, virilization in females); (3) endocrinologic testing. Baseline laboratory evaluation: serum 17-hydroxyprogesterone (elevated in 21-hydroxylase deficiency CAH), testosterone (elevated in androgen excess), DHEA-S (elevated in adrenal source of androgens), androstenedione (elevated in CAH), cortisol levels to assess for adrenal insufficiency (present in CAH). ACTH stimulation test (cosyntropin stimulation) is gold standard for CAH diagnosis if baseline screening suggests diagnosis. Imaging: abdominal ultrasound or adrenal CT if adrenal tumor suspected (palpable mass, unilateral androgen excess, adrenal enlargement >1.5 cm on ultrasound). Biopsy is not needed for diagnosis but histology shows sebaceous gland hyperplasia and inflammatory folliculitis similar to adolescent acne.

Treatment Algorithm

Endocrinology Referral: Essential first step for all infantile acne. Endocrinologists will perform appropriate hormone screening, ACTH stimulation testing if indicated, and imaging to identify underlying pathology. Treatment of underlying endocrine disease (if identified) may halt acne progression and prevent progression to severe acne.

Treatment of CAH: 21-hydroxylase deficiency CAH is treated with hydrocortisone (or prednisone at physiologic replacement doses 10-15 mg/m²/day divided in 2-3 doses) to suppress ACTH and normalize androgen production. With adequate corticosteroid replacement, acne typically improves within 4-8 weeks. Mineralocorticoid replacement (fludrocortisone) is also needed in salt-wasting CAH. Dosing requires careful titration with monitoring of growth, bone age, and hormone levels to avoid both under- and over-replacement.

Adrenal Tumor Management: Benign adenomas are treated by surgical resection (laparoscopic adrenalectomy) once diagnosed. Post-surgical androgen levels normalize quickly, with acne improvement within 2-4 weeks. Hormone replacement may be needed post-resection depending on degree of adrenal damage. Malignant adrenal tumors (rare) require chemotherapy (mitotane) in addition to surgical resection.

Topical Acne Therapy: While awaiting endocrinology evaluation and treatment of underlying disease, topical therapies provide symptomatic benefit. Benzoyl peroxide 2.5-5% applied once daily (lower concentrations for infant skin sensitivity) achieves 40-50% lesion reduction over 4-8 weeks. Avoid higher concentrations and systemic absorption-prone agents in infants. Topical antibiotics (clindamycin 1%, erythromycin 2%) are generally safe, though applied minimally given potential systemic absorption in infants.

Systemic Therapy: Oral antibiotics are generally avoided in infants unless severe inflammatory acne develops. If used, amoxicillin (not doxycycline or minocycline which are contraindicated in young children due to dental staining and bone effects) at age-appropriate doses. Isotretinoin is absolutely contraindicated in this age group.

Dermatologic Support: Gentle skin care with mild cleansers and non-comedogenic products. Avoid irritating topical agents. Monitor for secondary bacterial infection. Counseling to parents that infantile acne indicates need for endocrinologic evaluation and is not purely cosmetic issue but signal of potential systemic pathology.

Prognosis

Prognosis depends on underlying etiology: CAH with appropriate hydrocortisone replacement shows 80-90% improvement in acne within 4-8 weeks as androgen excess is controlled. Adrenal adenomas treated surgically show 85-95% clearance post-resection as androgens normalize. Idiopathic infantile acne of unclear etiology has variable course; if no abnormality identified, some spontaneously improve by 2-3 years of age while others persist requiring continued topical therapy. Early recognition and treatment prevent progression to severe nodular acne and permanent scarring. Identifying underlying CAH is critical not only for acne management but for overall health (CAH requires long-term corticosteroid and mineralocorticoid replacement to prevent adrenal crisis and other complications).

When to See a Dermatologist

Any infant with persistent acne beyond 3-4 months or acne with onset after 3-4 months should be evaluated by dermatology for confirmation and referral to pediatric endocrinology. Dermatologists can also manage topical therapy and provide supportive care while endocrinology investigates underlying causes.

Frequently Asked Questions

Q: Why does my baby have acne at 6 months old?
A: While neonatal acne is common and goes away on its own, acne persisting beyond 3-4 months or starting after that suggests your baby's body is producing too many androgens (a type of hormone). This requires medical investigation to identify the cause, which could be a treatable condition like an imbalance in adrenal hormone production.

Q: Could this be serious?
A: Infantile acne can indicate an underlying endocrine condition that requires treatment for your baby's health, not just for the skin. The most common cause is a condition called congenital adrenal hyperplasia (CAH), which is very treatable with hormone replacement. Early diagnosis and treatment prevent complications and help your baby's growth develop normally.

Q: What tests will my baby need?
A: An endocrinologist will typically order blood tests to measure hormone levels (especially from the adrenal glands), possibly an ACTH stimulation test, and sometimes imaging (ultrasound) to look at the adrenal glands. These tests are not painful and are important to find the cause of the acne.

Q: Will the acne go away once we treat the underlying cause?
A: Yes, in most cases, treating the underlying hormone imbalance results in acne improvement. If your baby has CAH and starts hydrocortisone replacement, acne typically improves significantly within 4-8 weeks. If there's an adrenal tumor (rare), surgical removal usually leads to rapid acne improvement.

References